DERMNasdaq

Journey Medical Corp

Healthcare·Oncology·Commercial·Scottsdale, AZ, United States
OncologyImmunologyInfectious DiseaseDermatology

Journey Medical Corp (DERM): 10 pipeline candidates · 4 upcoming catalysts · ~11 mo cash runway · 3 clinical trials. Updated within the last hour.

7.1/10

BioSniper Score

5-factor signal · derived from public data

Cash Runway3.2

11.4 months

Financial Health4.1

D/E 1.97

Pipeline Maturity10.0

Lead: Approved

Pipeline Breadth10.0

10 candidates

Catalyst Momentum8.0

4 upcoming, next in ~1566d

Insider SignalN/A

N/A

A transparent, data-derived signal for Journey Medical Corpacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.

Key Financials

Market Cap

$169.8M

Cash

$27.2M

Quarterly Burn

$10.1M

Runway

11.4 mo

Revenue

$16.0M

Cash Runway vs Catalysts

A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.

Cash ends ~May 2027
Today~166 mo out
Catalyst within runwayCatalyst after cash runs out

Pipeline (10 candidates)

Upcoming Catalysts (4)

Institutional Holdings

Source: SEC Form 13F · as of Mar 2026

Institutional holders

68

Total value held

$51.8M

HolderSharesValue
vanguard capital management llc2,164,160$10.1M
wasatch advisors lp2,133,370$10.0M
tang capital management llc1,610,000$7.6M
blackrock, inc.972,862$4.6M
j. goldman & co lp500,188$2.3M
geode capital management, llc463,202$2.2M
millennium management llc383,067$1.8M
summit financial, llc379,807$1.8M
ikarian capital, llc251,436$1.2M
renaissance technologies llc242,500$1.1M

Showing top 10 of 68 institutional holders of Journey Medical Corp. Sign up for the full 13F holder list and quarter-by-quarter ownership history.

3 clinical trials·6 FDA decisions·CEO: Mr. Claude Maraoui

Frequently asked questions

How many drug candidates are in Journey Medical Corp's pipeline?

Journey Medical Corp (DERM) has 10 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.

What is Journey Medical Corp's lead drug candidate?

Journey Medical Corp's most advanced tracked candidate is Accutane (Approved) for Severe recalcitrant nodular acne.

What is Journey Medical Corp's next catalyst?

Journey Medical Corp's next tracked catalyst is a Patent_Expiry event — "Patent/Exclusivity Expiry: ZILXI" — expected October 1, 2030.

What is Journey Medical Corp's cash runway?

Based on its most recent reported cash balance and quarterly burn rate, Journey Medical Corp has approximately 11.4 months of cash runway.

What is Journey Medical Corp's market capitalization?

Journey Medical Corp's market capitalization is approximately $169.8M.

Get the full picture on Journey Medical Corp

Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.